

CORRECTION

Open Access



Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

Qian Huang¹, Jiajia Xi¹, Lei Wang^{1,2}, Xu Wang¹, Xiaodong Ma^{1,2}, Qipan Deng¹, Yong Lu¹, Munish Kumar^{1,3}, Zhiyuan Zhou^{1,4}, Ling Li⁴, Zhaoyang Zeng⁵, Ken H. Young⁶, Qing Yi¹, Mingzhi Zhang⁴ and Yong Li^{1*}

Correction

The original article [1] contains a spelling error in the authorship; the authors would like to note the correct spelling of the second author, Jiajia Xi.

Author details

¹Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. ²Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou 510631, China. ³Raman Fellow (UGC), Department of Biochemistry, University of Allahabad, Allahabad, India. ⁴Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou 450000, Henan Province, China. ⁵Cancer Research Institute, Central South University, Changsha 410078, China. ⁶Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Received: 25 June 2018 Accepted: 25 June 2018

Published online: 03 July 2018

Reference

1. Huang Q, et al. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. *J Hematol Oncol*. 2018;11:58.

* Correspondence: liy2@ccf.org

¹Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

